Eastgate Biotech Corp.
ETBI
$0.00
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | ||||
|---|---|---|---|---|---|
| Revenue | -79.83% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -79.83% | -- | |||
| Cost of Revenue | 62.21% | -- | |||
| Gross Profit | -220.14% | -- | |||
| SG&A Expenses | 282.05% | -41.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 197.19% | -35.83% | |||
| Operating Income | -264.32% | 48.34% | |||
| Income Before Tax | -128.44% | 24.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -128.44% | 24.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -128.44% | 24.92% | |||
| EBIT | -264.32% | 48.34% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -25.00% | 60.00% | |||
| Normalized Basic EPS | -12.50% | 57.89% | |||
| EPS Diluted | -25.00% | 60.00% | |||
| Normalized Diluted EPS | -12.50% | 57.89% | |||
| Average Basic Shares Outstanding | 93.61% | 80.53% | |||
| Average Diluted Shares Outstanding | 93.61% | 80.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||